About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The goal of the Shock, Organic Dysfunction and Resuscitation Research Group (SODIR) is comprehensive, innovative research into the areas of shock, acute respiratory failure, acute kidney failure, organic dysfunction, resuscitation and critical patient monitoring. In addition, the research group has a special interest in applying artificial intelligence as an instrument to find innovative solutions for critical patients.
The line of research in acute respiratory failure has special interest in the study of the involvement of the interleukin 33 and its ST2 receptor in acute lung injury and its role as a possible therapeutic target. A model of acute lung injury in mice has been designed to show the prognostic efficacy of interleukin 33 and ST-2 plasma levels. Currently, SODIR is evaluating the possibility that treatment with anti-IL-33 antibodies may decrease the degree of inflammation in a murine experimental model of acute lung injury.
Another issue of special interest is the use of high flow nasal cannula supportive therapy. In this sense, SODIR has participated in a multicentric study, recently published in JAMA, analyzing the effect of high flow nasal cannula on postextubation respiratory failure.
Finally, SODIR is also involved in several multicentric international trials about the use of esophageal pressure to guide mechanical ventilation settings in patients with acute respiratory distress syndrome.
IP: Andres Francisco Pacheco Reyes, Juan Carlos Ruiz Rodriguez
The objective of research line of cardiac arrest and life support is to improve the knowledge about the inhospital cardiac arrest and to study more effective interventions during cardiac arrest and postresuscitation care that improve survival and life quality of the survived patients. SODIR also has a special interest in to identify the precipitating factors of the inhospital cardiac arrest and pericardiac arrest situations.
IP: Juan Carlos Ruiz Rodriguez
In close collaboration with the Oncology research group and the Hematology research group, the research line of Critical Oncohematology, has as a main objective the study of the complications associated to experimental treatments of the oncohematogy patients.
IP: Ricard Ferrer Roca
IP: Xavier Nuvials Casals
IP: Ibai Los Arcos Bertiz Collaborators: M Teresa Martin Gomez, Yolanda Villena Ortiz, Javier Gomis Rodriguez, Joan Gavaldà Santapau, Judith Sacanell Lacasa, Marta Zapata Ortega, Leire Sanchez Corujo Funding agency: Instituto de Salud Carlos III Funding: 37500 Reference: PI23/01467 Duration: 01/01/2024 - 31/12/2026
IP: Juan Jose Gonzalez Lopez Collaborators: Juan Carlos Ruiz Rodriguez Funding agency: EUROPEAN COMMISSION Funding: 269812 Reference: AMBROSIA_HE-CL4_22_DIGI-EMERG01 Duration: 01/01/2023 - 31/12/2026
IP: María Nieves Larrosa Escartin Collaborators: Jose Angel Rodrigo Pendás, Maria Belén Viñado Perez, Mª Carmen Ferrer Barberà, Nuria Fernández Hidalgo, Rosa Alcaraz Peñarrocha, Ma Dolores Rodríguez Pardo, Vanessa Casares Rodríguez, Albert Moreno Mingorance Funding agency: Instituto de Salud Carlos III Funding: 90750 Reference: PI21/01786 Duration: 01/01/2022 - 30/06/2026
The study will be conducted in the Intensive Care Medicine Service of the Vall d’Hebron University Hospital and will validate the prognostic value of the NLRP3 biomarker.
SOFA-2 is being updated after thirty years to incorporate advances in diagnosis, monitoring and life support.
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
